Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.

We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants. NCT02140255.

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [e-mail].

Déclaration de conflit d'intérêts

Potential conflicts of interest. D. P. received a one-time consultation fee from Merck to serve on their scientific advisory board, received an honorarium from the American Society of Pathology, provided expert testimony on behalf of the Children's Hospital of Philadelphia, and serves (unpaid) on the IAS Industry Collaborative Group. D. E. Y. was previously an unpaid technical advisor to the nonprofits Cover the Globe and Maipelo Trust and reports support from Astellas, Chimerix, and Viracor-Eurofins provided to his previous institution, prior to his current work at the National Institutes of Health. E. G. C.'s partner retired from and holds stock in AbbVie; she also received consulting fees from the National Clinicians Consultation Center and was paid for expert testimony by Brown & James P.C. A. C., B. S. N., C. P., C. T., D. P., E. G. C., J. J., M. F. C., S. A. S., and Y. B. report grants from the National Institutes of Health (NIH). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.